These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 12677176)

  • 1. Protective Molecules in Alzheimer's Disease: Therapeutic Antibodies.
    Solomon B
    Drug News Perspect; 2002 Sep; 15(7):410-416. PubMed ID: 12677176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Towards Alzheimer's beta-amyloid vaccination.
    Frenkel D; Solomon B
    Biologicals; 2001; 29(3-4):243-7. PubMed ID: 11851323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination for the prevention and treatment of Alzheimer's disease.
    Solomon B; Frenkel D
    Drugs Today (Barc); 2000 Sep; 36(9):655-63. PubMed ID: 12847570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease.
    Janus C; Pearson J; McLaurin J; Mathews PM; Jiang Y; Schmidt SD; Chishti MA; Horne P; Heslin D; French J; Mount HT; Nixon RA; Mercken M; Bergeron C; Fraser PE; St George-Hyslop P; Westaway D
    Nature; 2000 Dec 21-28; 408(6815):979-82. PubMed ID: 11140685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amyloid beta peptide immunotherapy in Alzheimer disease.
    Delrieu J; Ousset PJ; Voisin T; Vellas B
    Rev Neurol (Paris); 2014 Dec; 170(12):739-48. PubMed ID: 25459121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of P-glycoprotein Results in Impairment of Removal of Beta-Amyloid and Increased Intraparenchymal Cerebral Amyloid Angiopathy after Active Immunization in a Transgenic Mouse Model of Alzheimer's Disease.
    Bruckmann S; Brenn A; Grube M; Niedrig K; Holtfreter S; von Bohlen und Halbach O; Groschup M; Keller M; Vogelgesang S
    Curr Alzheimer Res; 2017; 14(6):656-667. PubMed ID: 27915995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of anti-beta-amyloid antibodies via phage display technology.
    Frenkel D; Dori M; Solomon B
    Vaccine; 2004 Jun; 22(19):2505-8. PubMed ID: 15193416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Developing injectable immunoglobulins to treat cognitive impairment in Alzheimer's disease.
    Steinitz M
    Expert Opin Biol Ther; 2008 May; 8(5):633-42. PubMed ID: 18407766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunological approaches for amyloid-beta clearance toward treatment for Alzheimer's disease.
    Solomon B
    Rejuvenation Res; 2008 Apr; 11(2):349-57. PubMed ID: 18341423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapeutic strategies for prevention and treatment of Alzheimer's disease.
    Solomon B
    DNA Cell Biol; 2001 Nov; 20(11):697-703. PubMed ID: 11788047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibodies from a DNA peptide vaccination decrease the brain amyloid burden in a mouse model of Alzheimer's disease.
    Schiltz JG; Salzer U; Mohajeri MH; Franke D; Heinrich J; Pavlovic J; Wollmer MA; Nitsch RM; Moelling K
    J Mol Med (Berl); 2004 Oct; 82(10):706-14. PubMed ID: 15241501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic effects of glatiramer acetate and grafted CD115⁺ monocytes in a mouse model of Alzheimer's disease.
    Koronyo Y; Salumbides BC; Sheyn J; Pelissier L; Li S; Ljubimov V; Moyseyev M; Daley D; Fuchs DT; Pham M; Black KL; Rentsendorj A; Koronyo-Hamaoui M
    Brain; 2015 Aug; 138(Pt 8):2399-422. PubMed ID: 26049087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elucidating the Structures of Amyloid Oligomers with Macrocyclic β-Hairpin Peptides: Insights into Alzheimer's Disease and Other Amyloid Diseases.
    Kreutzer AG; Nowick JS
    Acc Chem Res; 2018 Mar; 51(3):706-718. PubMed ID: 29508987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease.
    Morgan D; Diamond DM; Gottschall PE; Ugen KE; Dickey C; Hardy J; Duff K; Jantzen P; DiCarlo G; Wilcock D; Connor K; Hatcher J; Hope C; Gordon M; Arendash GW
    Nature; 2000 Dec 21-28; 408(6815):982-5. PubMed ID: 11140686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virosome-based active immunization targets soluble amyloid species rather than plaques in a transgenic mouse model of Alzheimer's disease.
    Zurbriggen R; Amacker M; Kammer AR; Westerfeld N; Borghgraef P; Van Leuven F; Van der Auwera I; Wera S
    J Mol Neurosci; 2005; 27(2):157-66. PubMed ID: 16186626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in the Development of Abeta-Related Therapeutic Strategies for Alzheimer's Disease.
    Barrow CJ
    Drug News Perspect; 2002 Mar; 15(2):102-109. PubMed ID: 12677216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alzheimer's disease and immunotherapy.
    Solomon B
    Curr Alzheimer Res; 2004 Aug; 1(3):149-63. PubMed ID: 15975063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beta-amyloidbased immunotherapy as a treatment of Alzheimers disease.
    Solomon B
    Drugs Today (Barc); 2007 May; 43(5):333-42. PubMed ID: 17724499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concomitant detection of beta-amyloid peptides with N-terminal truncation and different C-terminal endings in cortical plaques from cases with Alzheimer's disease, senile monkeys and triple transgenic mice.
    Härtig W; Goldhammer S; Bauer U; Wegner F; Wirths O; Bayer TA; Grosche J
    J Chem Neuroanat; 2010 Sep; 40(1):82-92. PubMed ID: 20347032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Vaccination therapy for Alzheimer's disease].
    Tabira T
    Brain Nerve; 2007 Apr; 59(4):375-82. PubMed ID: 17447524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.